Last Price
2.95
Today's Change
+0.20 (7.27%)
Day's Change
2.55 - 3.02
Trading Volume
237,097
Profile
FBLG
Exchange: Nasdaq Nasdaq
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Peter O'Heeron Mr. Peter O'Heeron
Full Time Employees: 10 10
IPO Date: 2024-02-01 2024-02-01
CIK: 0001958777 0001958777
ISIN: US31573L1052 US31573L1052
Beta: 0.00 0.00
Last Dividend: 0.00 0.00
Dcf Diff: 2.60 2.60
Dcf: 0.26 0.26
Description
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
US Goods Trade Deficit Surges to 2-1/2-year High on Jump in Imports
3
4
CEO Morning Brief
5
CEO Morning Brief
Meta Developing Its Own AI Search Engine, the Information Reports
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
